Sanofi to Acquire Vigil Neuroscience
Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.
Sanofi
20.02.2025 • News
Sanofi and CD&R Sign Share Purchase Agreement for Opella
Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).
04.12.2024 • News
Sanofi to Invest $1 Billion in New Insulin Manufacturing Site in China
Sanofi plans to invest around €1 billion ($1.1 billion) in the construction of a new insulin production facility in Beijing – the company's largest single investment in China to date. This was reported by Reuters and other news agencies.
21.10.2024 • News
Sanofi in Talks to Sell Stake in Opella to CD&R
Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.
14.05.2024 • News
Sanofi Invests €1 Billion to Boost Drug Manufacturing in France
On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
14.05.2024 • News
Sartorius and Sanofi Collaborate to Boost Downstream Process Efficiency
Life science group Sartorius and biopharmaceutical firm Sanofi are partnering to create a platform for continuous downstream bioprocessing. Sartorius will use its engineering and manufacturing skills to commercialize integrated and continuous biomanufacturing (ICB) platforms, using Sanofi’s prototypes. In exchange, Sanofi will provide Sartorius with exclusive access to its ICB platform knowledge and patents.
The Future of mRNA Technology
mRNA-based vaccines against the coronavirus have become firmly established in medicine since the pandemic. Nevertheless, the technology is still at the beginning of its potential. Experts see a wide range of potential applications for this relatively new technology, particularly in infectious diseases and cancer.
19.03.2024 • News
2024 Guidance Suspended: API Production Paused in Brindisi, Italy
EuroAPI today announces that its Italian subsidiary, EuroAPI Italy S.R.L., is suspending the production of all APIs (active pharmaceutical ingredients) in Brindisi.
18.03.2024 • News
Partex and Sanofi Partner for AI-Enhanced Dossier Improvement
Partex Group, an AI-driven drug discovery company, today announces a collaboration with global pharmaceutical company Sanofi, aimed at using Partex’s AI technology to enhance the value of Sanofi's out-licensing portfolio.
11.03.2024 • News
SK Bioscience to Expand South-Korean Vaccine Production Capacity
South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion.
23.01.2024 • News
Sanofi to Acquire Inhibrx for $1.7 Billion
Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.
04.12.2023 • News
SK Bioscience to Expand Production Capacity for Pneumococcal Vaccine in Korea
South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience wants to expand its vaccine manufacturing plant located in Andong, South Korea to approximately 4,200 m2 through joint investment with Sanofi.
04.10.2023 • News
Sanofi Enters into Partnerships with Janssen and Teva
Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, a potential first-in-class product currently in Phase 3.
Navigating Uncertainty in the Biopharma Market
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
29.03.2023 • News
Big Pharma Undercuts California Generic Insulin Plan
Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin scheme.
21.03.2023 • News
Global Pharma Reduces Marketing Staff in India
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.
20.03.2023 • News
Sanofi in Lockstep with US Insulin Price Cuts
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing sideward barbs at the system.
16.03.2023 • News
Novo Nordisk to Cut US Insulin prices from 2024
Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price cuts and in response to growing pressure from the White House.
15.03.2023 • News
Sanofi Buying Diabetes Specialist Provention Bio
Paris-based French drugmaker Sanofi has agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of about $2.9 billion. The publicly traded US biopharma focuses on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D).
14.03.2023 • News
Lilly Insulin Price Cut Revives US Discussion
As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly prescribed insulin products at the beginning of March.
19.01.2023 • News
Sanofi Strengthens Venture Capital Budget
As well as serving as a financial partner to fledgling companies, the VC fund supports future efforts for business development and M&A opportunities within its own operations, Sanofi said. The fresh capital injection will also fuel the expansion and investment capacity of its own investment team on a global scale.
12.01.2023 • News
EuroAPI Invests €40 Million in French B12 Production
Leading active pharmaceutical ingredients manufacturer EuroAPI plans to invest €40 million at its site in Saint-Aubin-lès-Elbeuf, France, to launch a new production technology for vitamin B12. Full capacity is expected to be reached by 2027.
15.11.2022 • News
Sanofi Enters Research Pact with Hong Kong’s Insilico
French pharma Sanofi has entered a multi-year, multi-target research collaboration worth up to $1.2 billion with Hong Kong biotech Insilico Medicine.
11.11.2022 • News
EU Approves Sanofi/GSK Covid Booster
After several delays and restarts and a lengthy review by the European Medicines Agency (EMA), the Covid-19 vaccine called VidPrevtyn Beta developed by the French-British partnership of Sanofi and GSK has been greenlighted by the European Commission.
08.11.2022 • News
Pharma CEOs Take Action on Climate Change
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
14.10.2022 • News
CDMO Adragos to Buy Sanofi Site in Japan
Munich-based German CDMO Adragos Pharma said it has signed a definitive agreement with Sanofi’s Japanese subsidiary to acquire a pharmaceutical manufacturing site in Kawagoe, near Tokyo.
Ensuring API Supply Capacities for Europe and Beyond
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
29.07.2022 • News
EuroAPI to Invest in Biomass Boiler in France
EuroAPI has announced it will spend €24 million to build a state-of-the-art biomass boiler at its Saint-Aubin-lès-Elbeuf (Seine-Maritime, France) site, planned to be installed by 2025.
05.07.2022 • News
Sanofi Joins Pfizer in nonprofit Drug Distribution
Two globally oriented drugmakers, Pfizer and Sanofi, are making moves that some may interpret as attempts to allay the pharma industry‘s reputation for being “only in it for the money” but could potentially benefit poorer countries if all goes to plan.
27.06.2022 • News • Innovation
New Covid Shots Score Points against Omicron
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
27.04.2022 • News
Sanofi Teams up with McLaren Racing
Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”
04.04.2022 • News
EuroAPI’s Euronext Listing Set for May 6
Sanofi has announced it will list its Active Pharmaceutical ingredients company EuroAPI on the Euronext stock exchange in Paris on May 6. Each of the French drugmaker’s shareholders will receive one share in EuroAPI for 23 Sanofi shares in addition to a cash dividend of €3.33 per Sanofi share.
31.03.2022 • News
Sanofi in Billion-Dollar Collaboration With IGM
French drugmaker Sanofi has signed an exclusive worldwide collaboration agreement with IGM Biosciences, a clinical-stage biotechnology company. The deal focuses on creating and developing and commercializing engineered IgM antibody antagonists against three oncology targets, along with three immunology/inflammation targets.
16.03.2022 • News
Sanofi and Blackstone in €300 Million Collaboration
Sanofi has agreed a €300 million collaboration with private equity investor Blackstone Life Sciences (BXLS) to advance its innovative treatment for multiple myeloma (MM) Sarclisa (isatuximab). The French drugmaker said it will continue to fully manage the clinical program and retain full rights and control of the treatment.
24.02.2022 • News
Sanofi and GSK Ready to Apply for Covid Vaccine Approval
After several delays, Sanofi and GlaxoSmithKline are preparing to submit data to regulatory authorities to support approval of their adjuvanted protein vaccine against Covid-19.
Infraserv GmbH & Co. Höchst KG
CHEManager International c/o Wiley-VCH GmbH
Sartorius AG
Berlin Partner für Wirtschaft und Technologie GmbH
Chemical Market Reporter
EvaluatePharma
F. Hoffmann-La Roche Ltd
Sanofi-Aventis Deutschland
Thomson Reuters
SchüllerConsulting
Ehrfeld Mikrotechnik GmbH
CONTINUUS Pharmaceuticals, Inc.
Metro Atlanta Chamber
Sanofi S.A.
Together for Sustanability (TFS)
Partex N.V.
Bayer AG
EuroAPI
GlobalData